4.3 Article

Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program

Journal

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 64, Issue 1, Pages 52-56

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2008.12.018

Keywords

Streptococcus pyogenes; Antimicrobial susceptibility; Surveillance; Macrolides; Cefditoren; Europe

Funding

  1. Spanish Ministry of Education and Science [CIT-090100-2007-12]
  2. Tedec-Meiji Farina, Madrid, Spain
  3. Comunidad de Madrid, Spain [COMBACT S-BIO-0260, CPI/0305/2007]
  4. Fundacion Conchita Rabago, Madrid, Spain
  5. European Union [E05D055472BR]

Ask authors/readers for more resources

The in vitro activity of penicillin, ampicillin, cefditoren, cefotaxime, erythromycin, clarithromycin, and levofloxacin against 763 clinical isolates of Streptococcus pyogenes was determined. Clinically significant isolates collected from November 2005 to December 2006 in the Czech Republic, Slovakia, Hungary, Poland, Romania, Estonia, Latvia, and Lithuania (the latter 3 analyzed as Baltic countries) were studied. No resistance to beta-lactams and levofloxacin was found. The rate of erythromycin resistance in S. pyogenes varied among countries, being low (<10%) in Romania and Baltic countries, intermediate (10-20%) in Poland and Czech Republic, and high (>25%) in Hungary and Slovakia. The predominant (75.0%) erythromycin-resistant phenotype among S. pyogenes isolates was MLSB. The identification of the prevalence of erythromycin resistance mechanism could have impact on the choice of empiric antibiotic therapy for the clinicians in such countries. (C) 2009 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available